"We thought there might be a preventive effect towards the development from CHIP to CCUS to MDS, so it’s a sort of a continuum," said Kirsten Grønbæk, MD, PhD.
|Articles|July 1, 2006
Oncology NEWS International
- Oncology NEWS International Vol 15 No 7
- Volume 15
- Issue 7
Phase III Trial of Enzastaurin for NHL Patients Initiated
Phase III Trial of Enzastaurin for NHL Patients Initiated
Advertisement
INDIANAPOLISEli Lilly has initiated a randomized, placebo- controlled phase III trial of its experimental agent enzastaurin as maintenance therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma (NHL) who have achieved remission after first-line therapy. In early clinical studies, enzastaurin, an oral serinethreonine kinase inhibitor, showed promising activity in NHL.
Articles in this issue
over 20 years ago
High-Quality Screening Colonoscopy Priority for GI Docsover 20 years ago
Genentech Seeks Expanded Use of Avastin in Breast Cancerover 20 years ago
Denosumab Suppresses Bone Resorption in Breast Ca Metsover 20 years ago
FDA Approves Priority Review of Merck's Zolinza (Vorinostat)over 20 years ago
FDA Approves Revlimid for Myeloma Rxover 20 years ago
Real-Time RT Planning, Delivery in the Bronxover 20 years ago
Racial Disparities in Prostate Ca Recurrenceover 20 years ago
HNPCC Pts May Reject Prophylactic Subtotal ColectomyNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
SubscribeAdvertisement
Related to this article
Ralph V. Boccia, MD, FACP, discussed how time since CAR T-cell therapy and toxicity profiles guide bispecific selection in relapsed multiple myeloma.
Al-Ola A. Abdallah, MD, explains a possible biological reason IMiD holding therapy benefited ide-cel but not cilta-cel recipients.
Industry payments to oncologists were associated with greater use of the promoted treatment, whether or not it was guideline-preferred for the patient’s cancer.
The phase 2/3 AHEAD-MERIT trial will continue to assess overall survival among patients who received BNT113 plus pembrolizumab for head and neck cancer.
Ralph V. Boccia, MD, FACP, discusses payer models, prior authorization, cost recovery, and patient assistance for bispecifics like teclistamab/daratumumab.
Robot-assisted radical hysterectomy reduced mostly low-grade intraoperative complications vs open surgery in early-stage cervical cancer.
Ralph V. Boccia, MD, FACP, explained why CAR T-cell therapy followed by bispecific antibodies may be the preferred sequence at first relapse in multiple myeloma.
Advertisement
Advertisement